GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amneal Pharmaceuticals Inc (NAS:AMRX) » Definitions » Accumulated other comprehensive income (loss)

AMRX (Amneal Pharmaceuticals) Accumulated other comprehensive income (loss) : $-30 Mil (As of Jun. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Amneal Pharmaceuticals Accumulated other comprehensive income (loss)?

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings. Amneal Pharmaceuticals's Accumulated other comprehensive income (loss) for the quarter that ended in Jun. 2024 was $-30 Mil.

Amneal Pharmaceuticals's quarterly Accumulated other comprehensive income (loss) increased from Dec. 2023 ($-32 Mil) to Mar. 2024 ($-24 Mil) but then declined from Mar. 2024 ($-24 Mil) to Jun. 2024 ($-30 Mil).

Amneal Pharmaceuticals's annual Accumulated other comprehensive income (loss) increased from Dec. 2021 ($-25 Mil) to Dec. 2022 ($10 Mil) but then declined from Dec. 2022 ($10 Mil) to Dec. 2023 ($-32 Mil).

Amneal Pharmaceuticals Accumulated other comprehensive income (loss) Historical Data

The historical data trend for Amneal Pharmaceuticals's Accumulated other comprehensive income (loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amneal Pharmaceuticals Accumulated other comprehensive income (loss) Chart

Amneal Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Accumulated other comprehensive income (loss)
Get a 7-Day Free Trial -0.07 -41.32 -24.83 9.94 -32.35

Amneal Pharmaceuticals Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Accumulated other comprehensive income (loss) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.08 3.87 -32.35 -23.71 -30.44

Amneal Pharmaceuticals Accumulated other comprehensive income (loss) Calculation

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings.

Amneal Pharmaceuticals Accumulated other comprehensive income (loss) Related Terms

Thank you for viewing the detailed overview of Amneal Pharmaceuticals's Accumulated other comprehensive income (loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

Amneal Pharmaceuticals Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amneal Pharmaceuticals Inc (NAS:AMRX) » Definitions » Accumulated other comprehensive income (loss)
Comparable Companies
PETQ HROW PAHC COLL EOLS SIGA PROC AVDL BKUH ORGO ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 SZSE:000538 XSWX:SDZ HKSE:03692
Traded in Other Exchanges
2DT:Germany
Address
400 Crossing Boulevard, 3rd Floor, Bridgewater, NJ, USA, 08807
Website
https://www.amneal.com
Amneal Pharmaceuticals Inc is a global pharmaceutical company operating primarily in the U.S., India, and Ireland. With three reportable segments; Generics, Specialty, and AvKARE - It develop, manufacture, and distribute a diverse portfolio of essential medicines. The Generics segment focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.
Executives
Andrew S Boyer officer: Exec VP, Comm Optns C/O WATSON PHARMA INC, 360 MOUNT KEMBLE AVE, MORRISTOWN NJ 07960
Nikita Shah officer: SVP, Chief HR Officer C/O AMNEAL PHARMACEUTICALS LLC, 400 CROSSING BLVD, BRIDGEWATER NJ 08807
Deborah M. Autor director C/O PARDES BIOSCIENCES, INC., 2173 SALK AVE., SUITE 250, PMB#052, CARLSBAD CA 92008
Tpg Gp A, Llc 10 percent owner 301 COMMERCE STREET, SUITE 3300, FORT WORTH TX 76102
Gustavo Pesquin officer: See Remarks 4 PARK LANE, MADISON NJ 07940
Jason B. Daly officer: SVP, Chief Legal Officer 400 CROSSING BLVD, 3RD FLOOR, BRIDGEWATER NJ 08807
Jon Winkelried 10 percent owner C/O GOLDMAN, SACHS & CO., 85 BROAD STREET, NEW YORK NY 10004
Gautam Patel director C/O AMNEAL PHARMACEUTICALS LLC, 400 CROSSING BLVD, BRIDGEWATER NJ 08807
Chirag K. Patel director C/O AMNEAL PHARMACEUTICALS LLC, 400 CROSSING BOULEVARD, BRIDGEWATER NJ 08807
Chintu Patel director C/O AMNEAL PHARMACEUTICALS LLC, 400 CROSSING BOULEVARD, BRIDGEWATER CA 08807
Joseph Todisco officer: SVP, Specialty Commercial 400 CROSSING BOULEVARD, BRIDGEWATER NJ 08807
John Kiely director C/O ZOVIO INC, 1811 E NORTHROP BLVD, CHANDLER AZ 85286
Jeffrey P. George director C/O AMNEAL PHARMACEUTICALS, INC., 400 CROSSING BOULEVARD, BRIDGEWATER NJ 08807
Shlomo Yanai director ONE MEADOWLANDS PLAZA, EAST RUTHERFORD NJ 07073
Paul M Meister director 18 SHIP ROCK ROAD, NORTH HAMPTON NH 03862